Category: Commences

  • CureVac Commences P-llb/lll Trial of CVnCoV for COVID-19

    Shots: The P-llb/lll HERALD trial will assess the safety and efficacy of CVnCoV (12 µg) in 35,000+ patients aged ≥18yrs. for the treatment of COVID-19 across EU and Latin America. The participants will receive a two-dose schedule of either CVnCoV or PBO The study will start with an initial P-IIb part, which is anticipated to […]